Plasma cystine/methionine ratio is associated with left ventricular diastolic function in patients with heart disease

Junko Asakura1, Manabu Nagao2, Masakazu Shinohara3,4

  • 1Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Heart and Vessels
|August 24, 2023
PubMed

Insights

Elevated homocysteine (Hcy) is linked to cardiovascular diseases. This study found a high cystine/methionine (CySS/Met) ratio is associated with diastolic dysfunction in heart disease patients, independent of other risk factors.

Area of Science:

  • Cardiology
  • Metabolomics
  • Biochemistry

Background:

  • Elevated circulating homocysteine (Hcy) is a known cardiovascular disease (CVD) risk factor.
  • The relationship between Hcy metabolites and left ventricular (LV) diastolic function is not well understood.
  • Diastolic dysfunction (DD) is a critical component of heart disease (HD).

Purpose of the Study:

  • To investigate the association between plasma Hcy-related metabolites and diastolic dysfunction (DD) in patients with heart disease (HD).
  • To determine if specific Hcy metabolites are independently associated with LV diastolic function markers.

Main Methods:

  • Sixty-two HD patients with preserved LV ejection fraction (LVEF ≥ 50%) were analyzed.
  • Plasma Hcy and its derivatives were quantified using liquid chromatography‒mass spectrometry (LC-MS/MS).
  • Spearman's correlation and multiple linear regression models were employed to assess metabolite-diastolic function relationships.

Main Results:

  • The cystine/methionine (CySS/Met) ratio showed a significant positive correlation with LV diastolic function (E/e' ratio).
  • Patients with higher E/e' values exhibited a significantly higher plasma CySS/Met ratio.
  • The CySS/Met ratio was independently associated with E/e' after adjusting for multiple clinical confounders.

Conclusions:

  • A high plasma CySS/Met ratio is indicative of diastolic dysfunction in heart disease patients.
  • The CySS/Met ratio may serve as a potential biomarker for assessing diastolic function in HD.
  • Further research is warranted to explore the mechanistic link between CySS/Met ratio and DD.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
119
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
23
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
23